Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Feb 12;12(2):e008189. doi: 10.1136/jitc-2023-008189

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

OS in (A) all randomized patients, (B) patients with tumor PD-L1 expression <1%, (C) patients with tumor PD-L1 expression ≥1%, (D) patients with squamous histology, and (E) patients with non-squamous histology. Minimum follow-up for OS was 47.9 months. 95% CIs for 4-year OS rates with nivolumab (NIVO) plus ipilimumab (IPI) with chemotherapy (Chemo) and chemotherapy alone, respectively, were: (A) 17–25 and 12–20; (B) 16–30 and 8–20; (C) 16–27 and 11–22; (D) 13–28 and 5–16; and (E) 17–27 and 14–24. OS, overall survival; PD-L1, programmed death ligand 1.